AstraZeneca PLC
AZN
$189.90
-$2.60-1.35%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.17% | 3.39% | -15.98% | 94.40% | 4.97% |
| Total Depreciation and Amortization | -24.47% | 11.52% | 8.18% | 103.81% | -65.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -187.10% | 300.93% | -77.05% | -106.58% | 865.63% |
| Change in Net Operating Assets | -243.83% | 342.03% | 19.01% | -21.71% | -953.66% |
| Cash from Operations | -54.38% | 51.62% | -8.81% | 27.73% | -14.07% |
| Capital Expenditure | -51.02% | -4.10% | -53.61% | 39.41% | -69.78% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | 800.00% | -50.00% | -- |
| Cash Acquisitions | 16.77% | -22.85% | 26.24% | -32.12% | -4.18% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.82% | 17.13% | -157.24% | -130.35% | 75.90% |
| Cash from Investing | 27.74% | 5.08% | -68.24% | -6.10% | 21.99% |
| Total Debt Issued | -187.50% | -154.66% | -41.40% | 292.13% | -37.83% |
| Total Debt Repaid | -2,166.67% | 19.13% | -35.29% | 28.57% | 94.30% |
| Issuance of Common Stock | 360.00% | 25.00% | -50.00% | -65.22% | 475.00% |
| Repurchase of Common Stock | 31.58% | -533.33% | 99.38% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -16,010.00% | 99.70% | -111,466.67% | 99.81% |
| Other Financing Activities | -9,700.00% | -50.00% | -101.92% | 485.19% | -212.50% |
| Cash from Financing | -58.32% | -500.19% | 119.14% | -303.43% | 83.76% |
| Foreign Exchange rate Adjustments | 133.33% | -141.38% | 16.00% | 140.98% | -405.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -327.29% | -42.58% | 922.07% | -122.33% | 144.34% |